BR112022026508A2 - Anticorpos que reconhecem sortilina - Google Patents

Anticorpos que reconhecem sortilina

Info

Publication number
BR112022026508A2
BR112022026508A2 BR112022026508A BR112022026508A BR112022026508A2 BR 112022026508 A2 BR112022026508 A2 BR 112022026508A2 BR 112022026508 A BR112022026508 A BR 112022026508A BR 112022026508 A BR112022026508 A BR 112022026508A BR 112022026508 A2 BR112022026508 A2 BR 112022026508A2
Authority
BR
Brazil
Prior art keywords
antibodies
sortilin
recognize
delay
changes
Prior art date
Application number
BR112022026508A
Other languages
English (en)
Inventor
James Dolan Philip Iii
Zago Wagner
Ioannou Andriani
S Nijjar Tarlochan
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of BR112022026508A2 publication Critical patent/BR112022026508A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

ANTICORPOS QUE RECONHECEM SORTILINA. A invenção fornece anticorpos que se ligam especificamente à sortilina. Os anticorpos inibem ou retardam as patologias associadas a alterações nos níveis de progranulina e deterioração sintomática associada.
BR112022026508A 2020-06-24 2021-06-23 Anticorpos que reconhecem sortilina BR112022026508A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063043481P 2020-06-24 2020-06-24
PCT/US2021/070764 WO2021263279A1 (en) 2020-06-24 2021-06-23 Antibodies recognizing sortilin

Publications (1)

Publication Number Publication Date
BR112022026508A2 true BR112022026508A2 (pt) 2023-03-07

Family

ID=79281994

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022026508A BR112022026508A2 (pt) 2020-06-24 2021-06-23 Anticorpos que reconhecem sortilina

Country Status (12)

Country Link
US (3) US20230235048A1 (pt)
EP (1) EP4171743A1 (pt)
JP (1) JP2023533458A (pt)
KR (1) KR20230026489A (pt)
CN (1) CN116249717A (pt)
AR (1) AR122736A1 (pt)
AU (1) AU2021297540A1 (pt)
BR (1) BR112022026508A2 (pt)
CA (1) CA3183994A1 (pt)
IL (1) IL299329A (pt)
TW (1) TW202216773A (pt)
WO (1) WO2021263279A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202342516A (zh) * 2021-12-23 2023-11-01 愛爾蘭商普羅希那生物科學有限公司 識別分選蛋白的抗體
WO2023247754A1 (en) 2022-06-23 2023-12-28 Draupnir Bio Aps Bifunctional molecules that selectively induce degradation of extracellular targets in lysosomes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007098184A2 (en) * 2006-02-21 2007-08-30 Nanogen, Inc. Methods and compositions for analyte detection
RU2603102C2 (ru) * 2009-12-10 2016-11-20 Ридженерон Фармасьютикалз, Инк. Мыши, которые производят антитела, имеющие только тяжелые цепи
PH12018501083A1 (en) * 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US9527913B2 (en) * 2012-05-02 2016-12-27 Symphogen A/S Humanized pan-HER antibody compositions
JP6999421B2 (ja) * 2015-04-07 2022-02-04 アレクトル エルエルシー 抗ソルチリン抗体及びその使用方法

Also Published As

Publication number Publication date
JP2023533458A (ja) 2023-08-03
AU2021297540A1 (en) 2023-02-02
US20240117040A1 (en) 2024-04-11
US20230235048A1 (en) 2023-07-27
IL299329A (en) 2023-02-01
EP4171743A1 (en) 2023-05-03
TW202216773A (zh) 2022-05-01
KR20230026489A (ko) 2023-02-24
WO2021263279A1 (en) 2021-12-30
AR122736A1 (es) 2022-10-05
US20240117039A1 (en) 2024-04-11
CA3183994A1 (en) 2021-12-30
CN116249717A (zh) 2023-06-09

Similar Documents

Publication Publication Date Title
BR112021016947A2 (pt) Anticorpos que reconhecem tau
BR112019022906A2 (pt) Anticorpos que reconhecem tau
BR112018072389A2 (pt) anticorpos que reconhecem tau
BR112022017930A2 (pt) Anticorpos anticoronavírus e métodos de uso
BR112022026508A2 (pt) Anticorpos que reconhecem sortilina
BR112018072394A2 (pt) anticorpos que reconhecem a tau
CO2021011140A2 (es) Anticuerpos que reconocen tau
CU24446B1 (es) Un anticuerpo monoclonal humanizado que se une a tau
CL2018003205A1 (es) Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de tnf y un resto de unión a pd1.
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
EA202190542A1 (ru) Сконструированные биспецифические белки
CO2021007370A2 (es) Anticuerpos que reconocen tau
EA201991769A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ С НИЗКИМ ПОКАЗАТЕЛЕМ pH, СОДЕРЖАЩАЯ КОНСТРУКЦИИ НА ОСНОВЕ АНТИТЕЛА, ОСУЩЕСТВЛЯЮЩИЕ РЕКРУТИНГ Т-КЛЕТОК
BR112019004990A2 (pt) anticorpo que se liga especificamente a il-17a e fragmento funcional do mesmo
CU20210039A7 (es) Anticuerpos que reconocen tau
BR112016020366A2 (pt) anticorpos anti-eotaxina-2 que reconhecem quimiocinas de ligação a ccr3 adicionais
BR112021013397A2 (pt) Anticorpos anti-tigit
BR112021004316A2 (pt) Anticorpos de agonistas anti-trem-2
CL2023001064A1 (es) Proteína de unión al antígeno anti-steap1
MA55600A (fr) Anticorps anti-ige
CL2020002459A1 (es) Variantes de anticuerpo c-terminales
EA202190772A1 (ru) Панельный элемент
AR128076A1 (es) Anticuerpos que reconocen la sortilina
EA202191306A1 (ru) Антитела, распознающие тау
CO2021008755A2 (es) Anticuerpo que se une a vegf y a il-1beta y métodos de utilización